Factors associated to adequate time in therapeutic range with oral vitamin K antagonists in Tunisia

##plugins.themes.academic_pro.article.sidebar##

Published Apr 18, 2019
Download
pdf
Vol. 97 No. 1 (2019): Issue Jan 2019

##plugins.themes.academic_pro.article.main##

Sana Ouali
Mahdi Mechri
Zine Ben Ali
Selim Boudiche
Manel Ben Halima
Salabil Rejaibi
Mohamed Sami Mourali
Noureddine Larbi
Fathia Meghaieth

Abstract

Introduction:  The quality of chronic anticoagulation and predictor factors of poor anticoagulant control in patients under acenocoumarol were unknown in North Africa. 
Methods: It is an observational study, carried out between November 2015 and November 30, 2016. The international normalized ratio (INR) values were prospectively obtained, and TTR was calculated using the Rosendaal method.
Results: Overall, 215 patients were included in this study, with a mean age of 63±0,8 years. The prevalence of poor anticoagulation control was 78.1%; 95% CI [72.2-83.2] (168 patients with TTR less than 65%). The median TTR with the Rosendaal method was 44.4%. After multivariate adjustment, variables significantly associated with adequate anticoagulation level were: history of ischemic stroke (Adjusted OR equal to 4.3, 95% CI: 1.4-12.9), associated prescription of antiplatelet therapy (Adjusted OR equal to 3.5, 95% CI: 1.1-11.2), daily prescribed dose of coumarins less than 6 mg (Adjusted OR equal to 6.4, 95% CI: 1.1- 36) and lower risk of bleeding assessed as HAS-BLED score (Adjusted OR: 0.5, 95% CI: 0.3-0.8).
Conclusion: The quality of anticoagulation management with VKA among outpatients who received acenocoumarol was suboptimal. Strategies should be undertaken by clinicians and patients to improve the quality of anticoagulation, to address challenges to adverse cardiovascular outcomes in individuals treated with chronic anticoagulation.

Keywords:

acenocoumarol, time in therapeutic range, anticoagulation

##plugins.themes.academic_pro.article.details##

References

  1. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e326S-e50S.
  2. Schulman S. Advantages and limitations of the new anticoagulants. J Intern Med. 2014;275:1-11.
  3. Veeger NJ, Piersma-Wichers M, Tijssen JG, et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol. 2005;128:513-519.
  4. Van Spall HG, Wallentin L, Yusuf S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2012;126:2309-16.
  5. Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with nonvalvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005;91:472-477.
  6. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029-37.
  7. Mearns ES, White CM, Kohn CG, et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J. 2014;12:14.
  8. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-9.
  9. Evers T, O'Neil WM, Ogilvie IM, Welner SA, Lip G. PCV144 Stroke Prevention in Patients with Atrial Fibrillation: Inappropriate Anticoagulation and Poor INR Control. Value in Health. 2011;14:A390.
  10. Chapman SA, St Hill CA, Little MM, et al. Adherence to treatment guidelines: the association between stroke risk stratified comparing CHADS2 and CHA2DS2-VASc score levels and warfarin prescription for adult patients with atrial fibrillation. BMC Health Serv Res. 2017;17:127.
  11. Claridge SB, Kanaganayagam GS, Kotecha T. Atrial fibrillation guidelines. Don't forget HASBLED score. BMJ. 2011;342:d3205.
  12. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: The SAMe-TT2R2 score. Chest. 2013;144:1555-63.
  13. Kaatz S. Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis. 2008;25:61-66.
  14. Phillips K, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Expert Rev Cardiovasc Ther. 2008;6:57-70.
  15. Wunsch H, Linde-Zwirble WT, Angus DC. Methods to adjust for bias and confounding in critical care health services research involving observational data. J Crit Care. 2006;21:1-7.
  16. Fenta TG, Assefa T, Alemayehu B. Quality of anticoagulation management with warfarin among outpatients in a tertiary hospital in Addis Ababa, Ethiopia: a retrospective cross-sectional study. BMC Health Serv Res. 2017;17:389.
  17. McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of Warfarin use for patients with Arial fibrillation in the long-term care setting. Arch Intern med. 2001;161:2458-63.
  18. Verhovsek M, Motlagh B, Crowther MA, et al. Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review. BMC Geriatr. 2008;8:13.
  19. Shin H, Kim Y, Bae H, Lee H, Cho H, Cho Y. Trends in oral anticoagulation therapy among Korean patients with Atrial fibrillation: the KORean Atrial fibrillation investigation. Korean Circ J. 2012;42:113-7.
  20. Alyousif SM, Alsaileek AA. Quality of anticoagulation control among patients with atrial fibrillation: An experience of a tertiary care center in Saudi Arabia. J Saudi Heart Assoc. 2016;28:239-43.
  21. Sonuga BO, Hellenberg DA, Cupido CS, Jaeger C. Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa. Afr J Prim Health Care Fam Med. 2016;8:e1-8
  22. Maeder MT, König T, Bogdanovic S, et al. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland. Swiss Med Wkly. 2017;147:w14503.
  23. Pattacini C, Manotti C, Pini M, Quintavalla R, Dettori AG. A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol). Thromb Haemost. 1994; 71: 188-191.
  24. 24. Undas A, Cieśla-Dul M, Zółciński M, Tracz W. Switching from acenocoumarol to warfarin in patients with unstable anticoagulation and its effect on anticoagulation control. Pol Arch Med Wewn. 2009; 119: 360-365.
  25. Bryk AH, Plens K, Undas A. Prediction of unstable anticoagulation with acenocoumarol versus warfarin in atrial fibrillation. Cardiol J. 2017;24:477-483.
  26. Mohammed S, Aljundi AH, Kasem M, Alhashemi M, El-Menyar A. Anticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience. J Adv Pharm Technol Res. 2017;8:14-18.
  27. Estrada CA, Martin-Hryniewicz M, Peek BT, et al. Literacy and numeracy skills and anticoagulation control. Am J Med Sci. 2004; 328:88-93.
  28. Oramasionwu CU, Bailey SC, Duffey KE, et al. The association of health literacy with time in therapeutic range for patients on warfarin therapy. J Health Commun. 2014; 19(Suppl 2):19-28.
  29. Ferguson C, Inglis SC, Newton PJ, Middleton S, Macdonald PS, Davidson PM. Barriers and enablers to adherence to anticoagulation in heart failure with atrial fibrillation: patient and provider perspectives. J Clin Nurs. 2017;26:4325-4334.
  30. Reading SR, Go AS, Fang MC, et al. Anticoagulation and Risk Factors in Atrial Fibrillation-Cardiovascular Research Network (ATRIAâ€CVRN) Investigators. Health Literacy and Awareness of Atrial Fibrillation. J Am Heart Assoc. 2017; 6:e005128.
  31. Martins MAP, Costa JM, Mambrini JVM, et al. Health literacy and warfarin therapy at two anticoagulation clinics in Brazil. Heart. 2017;103:1089-1095.
  32. Pandya EY, Bajorek B. Factors affecting patients' perception on, and adherence to, anticoagulant therapy: anticipating the role of direct oral anticoagulants. Patient. 2017;10:163-185.
  33. Talboom-Kamp EPWA, Verdijk NA, et al. Effect of a combined education and eHealth programme on the control of oral anticoagulation patients (PORTALS study): a parallel cohort design in Dutch primary care. BMJ Open. 2017;7:e017909.
  34. Clarkesmith DE, Pattison HM, Khaing PH, Lane DA. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation (Review). Cochrane Database of Systematic Reviews 2017, Issue 4.
  35. Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self- monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematolo. 2009;126: 557-64.
  36. Esteve-Pastor MA, Rivera-Caravaca JM, Roldán-Rabadán I, et al. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. Europace. 2017;0:1-7.
  37. Tong HY, Davila-Fajardo CL, Borobia AM, et al. A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. PLoS One. 2016;11:e0150456.
  38. Verhoef TI, Ragia G, de Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med. 2013;369:2304-12.
  39. Proietti M, Lip GY. Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score. Eur Heart J Cardiovasc Pharmacother. 2015;1:150-2.
  40. Lobos-Bejarano JM, Barrios V, Polo-García J, Escobar C, et al. On behalf the PAULA Study Team. Evaluation of SAMe-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain. Curr Med Res Opin. 2016; 32: 1201-7.
  41. Tajer C, Ceresetto J, Bottaro FJ, Martí A, Casey M; TERRA Trial investigators. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina. Clin Appl Thromb Hemost. 2017;23:445-453.
  42. Pokorney SD, Simon DN, Thomas L, et al. Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. JAMA. 2016; 316:661-3.